Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:GUTS NASDAQ:LUNG NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$13.54+2.0%$11.91$6.55▼$14.00$64.23M-0.066,239 shs2,395 shsGUTSFractyl Health$1.34-3.6%$1.14$0.83▼$3.48$69.90M2.277.44 million shs737,230 shsLUNGPulmonx$1.61-3.6%$1.67$1.47▼$9.37$68.05M0.42272,173 shs182,097 shsVVOSVivos Therapeutics$2.76-3.2%$3.69$1.98▼$7.95$21.39M6.9277,764 shs369,673 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+1.96%+5.53%+13.97%+40.60%+48.30%GUTSFractyl Health-3.60%-0.74%+35.56%-30.21%-48.66%LUNGPulmonx-3.59%+2.55%-4.73%-57.41%-74.20%VVOSVivos Therapeutics-3.16%-13.21%-19.77%-50.80%+2.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$13.54+2.0%$11.91$6.55▼$14.00$64.23M-0.066,239 shs2,395 shsGUTSFractyl Health$1.34-3.6%$1.14$0.83▼$3.48$69.90M2.277.44 million shs737,230 shsLUNGPulmonx$1.61-3.6%$1.67$1.47▼$9.37$68.05M0.42272,173 shs182,097 shsVVOSVivos Therapeutics$2.76-3.2%$3.69$1.98▼$7.95$21.39M6.9277,764 shs369,673 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+1.96%+5.53%+13.97%+40.60%+48.30%GUTSFractyl Health-3.60%-0.74%+35.56%-30.21%-48.66%LUNGPulmonx-3.59%+2.55%-4.73%-57.41%-74.20%VVOSVivos Therapeutics-3.16%-13.21%-19.77%-50.80%+2.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 2.50Moderate Buy$25.0084.64% UpsideGUTSFractyl Health 2.60Moderate Buy$6.90414.93% UpsideLUNGPulmonx 2.40Hold$7.66376.04% UpsideVVOSVivos Therapeutics 2.00Hold$4.9278.14% UpsideCurrent Analyst Ratings BreakdownLatest VVOS, GUTS, LUNG, and DXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DXRDaxorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025GUTSFractyl HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LUNGPulmonxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025VVOSVivos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DXRDaxorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025GUTSFractyl HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LUNGPulmonxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VVOSVivos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025GUTSFractyl HealthHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.009/15/2025GUTSFractyl HealthHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.009/9/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.20 ➝ $6.50(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AGUTSFractyl Health$17K3,963.96N/AN/A$0.59 per share2.27LUNGPulmonx$83.79M0.78N/AN/A$2.17 per share0.74VVOSVivos Therapeutics$15.03M1.38N/AN/A$1.35 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AGUTSFractyl Health-$68.69M-$2.06N/AN/AN/AN/A-584.35%-102.88%11/11/2025 (Estimated)LUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-69.76%-36.26%10/29/2025 (Estimated)VVOSVivos Therapeutics-$11.14M-$1.68N/AN/AN/A-99.49%-232.76%-84.30%11/13/2025 (Estimated)Latest VVOS, GUTS, LUNG, and DXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025VVOSVivos Therapeutics-$0.50N/AN/AN/A$4.49 millionN/A11/11/2025Q3 2025GUTSFractyl Health-$0.34N/AN/AN/AN/AN/A10/29/2025Q3 2025LUNGPulmonx-$0.40N/AN/AN/A$20.78 millionN/A8/19/2025Q2 2025VVOSVivos Therapeutics-$0.39-$0.55-$0.16-$0.55$3.37 million$3.82 million8/12/2025Q2 2025GUTSFractyl Health-$0.37-$0.53-$0.16-$0.57N/AN/A7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AGUTSFractyl Health4.611.221.22LUNGPulmonx0.545.354.63VVOSVivos Therapeutics1.691.051.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%GUTSFractyl HealthN/ALUNGPulmonx91.04%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%GUTSFractyl Health26.10%LUNGPulmonx6.80%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableGUTSFractyl Health10250.29 million37.16 millionN/ALUNGPulmonx25040.75 million37.98 millionOptionableVVOSVivos Therapeutics1607.50 million7.35 millionOptionableVVOS, GUTS, LUNG, and DXR HeadlinesRecent News About These CompaniesShort Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Grows By 122.8%October 20 at 2:53 AM | americanbankingnews.comVivos Therapeutics announces additional data from use of Vivos DNA deviceSeptember 30, 2025 | msn.comVivos Therapeutics Reports Clinical Data Showing Significant Improvement in ADHD and OSA Symptoms in Children Using FDA-Cleared DNA ApplianceSeptember 30, 2025 | quiverquant.comQVivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA DeviceSeptember 30, 2025 | globenewswire.comVivos Therapeutics announces trial results in pediatric OSA treatmentSeptember 17, 2025 | msn.comVivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea TreatmentSeptember 17, 2025 | globenewswire.comVivos Therapeutics’ Earnings Call: Strategic Transition and GrowthAugust 31, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call TranscriptAugust 22, 2025 | seekingalpha.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2025 Earnings Call TranscriptAugust 21, 2025 | msn.comVivos Reports 7% Sales DropAugust 21, 2025 | aol.comAVivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 20, 2025 | finanznachrichten.deVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 19, 2025 | globenewswire.comVivos Therapeutics, Inc. Announces Upcoming Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | quiverquant.comQVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | globenewswire.comVivos Therapeutics Delays Q2 2025 10-Q FilingAugust 14, 2025 | msn.comVivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30, 2025 | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Abbott Laboratories' October Price Plunge Is a Signal to BuyBy Thomas Hughes | October 17, 2025VVOS, GUTS, LUNG, and DXR Company DescriptionsDaxor NASDAQ:DXR$13.54 +0.26 (+1.96%) As of 10/21/2025 03:55 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Fractyl Health NASDAQ:GUTS$1.34 -0.05 (-3.60%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.32 -0.02 (-1.12%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Pulmonx NASDAQ:LUNG$1.61 -0.06 (-3.59%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.64 +0.02 (+1.55%) As of 10/21/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Vivos Therapeutics NASDAQ:VVOS$2.76 -0.09 (-3.16%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$2.72 -0.04 (-1.41%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
